^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ESP-01

    i
    Other names: LY2880070, ESP-01, ESP 01, LY 2880070
    Associations

    News

    Trials
    Company:
    Esperas
    Drug class:
    Chk1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=229, Recruiting, Esperas Pharma Inc. | Phase classification: P1b/2a --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER expression
    |
    gemcitabine • ESP-01
    2ms
    A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor (clinicaltrials.gov)
    P2, N=24, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    WT1 (WT1 Transcription Factor) • BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1) • ETV1 (ETS Variant Transcription Factor 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • ETV4 (ETS Variant Transcription Factor 4)
    |
    EWSR1-WT1 fusion
    |
    gemcitabine • ESP-01
    over1year
    A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1b/2a, N=229, Recruiting, Esperas Pharma Inc. | Completed --> Recruiting | N=119 --> 229 | Trial completion date: Jan 2022 --> Sep 2025 | Trial primary completion date: Jan 2022 --> Sep 2025
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER expression
    |
    gemcitabine • ESP-01
    2years
    A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1b/2a, N=119, Completed, Esperas Pharma Inc. | Recruiting --> Completed | N=185 --> 119 | Trial completion date: Jun 2021 --> Jan 2022 | Trial primary completion date: Mar 2020 --> Jan 2022
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER expression
    |
    gemcitabine • ESP-01
    2years
    A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma or Ewing-Like Sarcoma (clinicaltrials.gov)
    P2, N=24, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial • Combination therapy
    |
    EWSR1 (EWS RNA Binding Protein 1) • ETV1 (ETS Variant Transcription Factor 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • ETV4 (ETS Variant Transcription Factor 4)
    |
    gemcitabine • ESP-01
    almost4years
    A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1b/2a, N=185, Recruiting, Esperas Pharma Inc. | Active, not recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER expression
    |
    gemcitabine • ESP-01
    4years
    A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1b/2a, N=185, Active, not recruiting, Esperas Pharma Inc. | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER expression
    |
    gemcitabine • ESP-01
    over4years
    A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1b/2a, N=185, Recruiting, Esperas Pharma Inc. | Trial primary completion date: Dec 2019 --> Mar 2020
    Clinical • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER expression
    |
    gemcitabine • ESP-01